Continued use of tamoxifen may make your periods less regular, lighter or stop altogether. When you start taking tamoxifen it may stimulate the release of an egg from the ovary (ovulation) and could make you more fertile. It’s possible to become pregnant while taking tamoxifen even if your periods have become irregular or stopped. Taking tamoxifen while pregnant may be harmful to a developing baby. Ask your treatment team or pharmacist before taking any herbal products or supplements. If this is the case, your treatment team may suggest an alternative. Thankfully, Gynectrol promotes muscle gain through naturally increasing testosterone (you should also notice a nice increase in your libido and energy levels). It can eliminate the need for expensive surgery or hormone replacement therapy. This drug works well for many people using it for this purpose, but not everyone will have the same positive results. This is exactly what we need to be happening to stop gynecomastia from occurring as estrogen-related negative effects of many AAS. This makes AIs not so appealing for on-cycle use as Nolvadex or other SERMs, and as I mentioned earlier, Nolvadex can potentially positively impact cholesterol. It’s excellent for PCT use alongside other ancillaries (especially hCG), and I’m confident that it will give you the PCT recovery we all need with minimal side effects. You can use it effectively at a lower dose, and it gives me fewer side effects troubles than Clomid. Nolvadex will help normalize your endogenous testosterone production, so yes, it will help. Based on the aforementioned discussions, I believe that any assertion that a drug should not be used to treat certain diseases should be based on sufficient evidence, especially when the assertion would hinder the further combination therapy of this drug. Therefore, the rationale of combined tamoxifen or low doses of human chorionic gonadotropin with testosterone at an appropriate dose lies in the overstimulation of pituitary gonadotropin and Leydig/Sertoli cell secretion simultaneously with overstimulation of accessory gland secretion and epididymal function. In addition, Hsieh et al.24 demonstrated that intratesticular testosterone could be maintained during testosterone replacement therapy by coadministration of a low dose of human chorionic gonadotropin, which could support continued spermatogenesis in patients on testosterone replacement therapy. The relative androgen deficiency that occurred in aberrations of the sperm parameters was most likely not fully compensated by tamoxifen.22 In this context, administration of androgen at a low dose does not compromise central and peripheral hormone secretion and might be appropriate for stimulating epididymal function independently of Leydig cell activity, and thus, might improve sperm quality. Adamopoulos et al.15 administered short- (10-day) or long-term (3-month) TU (40 mg t.i.d.) to treat idiopathic oligozoospermia and demonstrated that no marked effect by any type of treatment, including TU administration at the dose that was given or in combination with tamoxifen, was seen in either central or peripheral secretory activity. Various clinical testosterone deficiencies, such as congenital defects of testosterone synthase, Leydig cell hypoplasia, androgen receptor gene mutation induced by androgen insensitivity syndrome, Kallmann syndrome or other congenital or acquired defects of gonadotropin could cause disorders in spermatogenesis or even azoospermia. If you have a significant family history and are taking tamoxifen to reduce your risk of breast cancer developing, you’ll usually take it for 5 years. If you’re being treated for primary breast cancer, you will usually take tamoxifen for between 5 and 10 years. Tamoxifen may be an option for some women who do not have breast cancer but have a higher risk of developing it because of their family history. Read more about the treatment options for secondary breast cancer you may be offered. If you have an early type of breast cancer called DCIS, the benefits of tamoxifen are less clear. This stops oestrogen from helping the breast cancer cells grow. Some breast cancers use oestrogen in the body to help them grow. Nolvadex is valued for PCT purposes thanks to its ability to speed up the recovery of your natural testosterone production after it has been suppressed or shut down by anabolic steroids. The only reason we will use Nolvadex during a steroid cycle is to either completely prevent gyno from developing or as a measure to reverse the first signs of gyno if they begin to show at any point in the cycle. Always pair with bloodwork to monitor hormone recovery and consult a healthcare professional. On-cycle use of Nolvadex to protect against male breast enlargement is an established anabolic steroid user protocol. SERMs, on the other hand, are targeted to certain parts of the body and only bind to estrogen receptors rather than actively lowering serum estrogen levels. The other reason we’re interested in SERMs like Nolvadex is their ability to stimulate testosterone production after a suppressive steroid cycle, as they promote the release of the luteinizing hormone and the follicle-stimulating hormone. Nolvadex effectively takes the place of estrogen in breast tissue – precisely where we need it to be to stop dreaded gyno on cycle. The use of Nolvadex for male infertility is directly related to why and how we use Nolvadex in a PCT setting. To circumvent the inhibition of LH and FSH from the pituitary by exogenous testosterone, a common strategy used by male reproductive and sexual medicine specialists, in which the goal is to increase testosterone levels while maintaining spermatogenesis, is to use SERMs and/or AIs instead of exogenous testosterone (Figure 1). Any other effort and approaches toward the challenge of treating male infertility should not be discouraged outside the framework of ART, which are also a type of empirical medicine. The rapid development of symptomatic medical science (such as ART technology) is a double-edged sword, and to some extent, it prevents exploration of routine therapies for male infertility. Specifically, two-thirds of American urologists who were questioned would apply an empirical drug therapy approach.29 According to national experience but without detailed data, empirical drug application (including testosterone supplementation) is perhaps applied even more widely, and experts and scientific teams cannot neglect the objectivity and rationale of this phenomenon. In addition, TU administration (40 mg t.i.d.) could result in a marked increase in serum dihydrotestosterone (DHT) without appreciable gonadotropin changes;2,23 therefore, one may speculate that this increase is instrumental in bringing about the beneficial effects on sperm parameters after TU and tamoxifen coadministration. This selective estrogen receptor modulator (SERM) is used to treat and prevent breast cancer by blocking the effects of estrogen in breast tissue. Tamoxifen is a selective estrogen receptor modulator (SERM) that is commonly used to treat and prevent estrogen receptor-positive breast cancer. Tamoxifen, initially developed as a treatment for breast cancer, has gained recognition for its ability to block estrogen receptors in breast tissue. Much of the data stem from boys with pubertal gynecomastia and in men with prostate cancer on antiandrogen therapy; there is evidence that these medications are effective in the treatment of gynecomastia.43-45 Their use in the treatment of gynecomastia induced by exogenous testosterone therapy is largely anecdotal and not evidence based.46 However, the manipulation of estrogen levels in men may not be without consequences. Although the studies on tamoxifen use in men have largely focused on those with infertility, its mechanism of action suggests it can also be used to raise testosterone levels in men with low testosterone who possibly may have relatively elevated serum estradiol levels. Moreover, all men reported improvements in post-treatment quality of life scores.17 Other studies have also found that aside from improvement in serum testosterone levels, clomiphene therapy also leads to significant improvement in bone mineral density, as well as androgen deficiency in the aging male (ADAM) scores without any significant adverse events.18,19 Empirical drug treatment of male infertility will remain empirical until it is validated by sufficient evidence-based medicine.
